ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19
Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
This study looks at the safety and effectiveness of different drugs in treating COVID-19 in
people who have been hospitalized with the infection and who have acute respiratory failure.
Participants in the study will be treated with either a study drug plus current standard of
care (SOC), or with placebo plus current SOC.
Phase:
Phase 3
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators:
AIDS Clinical Trials Group Cardiothoracic Surgical Trials Network (CTSN) Gilead Sciences International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) Kirby Institute Medical Research Council National Heart, Lung, and Blood Institute (NHLBI) NeuroRx, Inc. Prevention and Early Treatment of Acute Lung Injury (PETAL) University of Copenhagen US Department of Veterans Affairs Washington D.C. Veterans Affairs Medical Center